Fourth Quarter & Full Year 2022 Financial & Business Update

Strong Commercial Execution Across Brands & ADCETRIS brentuximab vedotin I for injection ADCETRIS is the foundation of care for CD30- expressing lymphomas • . Record quarterly sales driven by normalizing diagnosis rates, price, and incremental share gains in 1L CHL Now a NCCN category 1 preferred regimen in 1L CHL • 'TUKYSA tucatinib 50 mg 150 mg tablets TUKYSA regimen remains an important treatment option in 2L+ HER2 metastatic breast cancer • patients, especially with CNS involvement Commercial team has now launched the product into the second line plus setting in HER2+ mCRC >120k patients treated to date across portfolio with brand growth fueled by expanded commercialization engine scaled for future launches Seagen PADCEV enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials PADCEV is a U.S. standard of care in mUC for the post-platinum/CPI treatment setting 4Q22 sales grew +32% YoY Planning for potential label expansion in 1L cisplatin-ineligible mUC patients in mid-2023 tivdak tisotumab vedotin-tftv for injection 40 mg TIVDAK First-in-Class ADC for Metastatic Cervical Cancer • Now a NCCN preferred regimen in 2L+ recurrent or metastatic cervical cancer • Well-positioned in 2L/3L setting; area of high unmet need 16

View entire presentation